OR WAIT null SECS
Jennifer Grebow is editor-in-chief of Nutritional Outlook.
Gencor, Levagen’s supplier, says the ingredient has been clinically shown to benefit those suffering from joint discomfort, and that it also supports a healthy anti-inflammatory response.
A new, branded palmitoylethanolamide (PEA) ingredient for joint health called Levagen will make its debut at November’s SupplySide West trade show. Gencor (Irvine, CA), Levagen’s supplier, says the ingredient has been clinically shown to benefit those suffering from joint discomfort, and that it also supports a healthy anti-inflammatory response.
“PEA was first identified in the 1950s as a therapeutic substance with potential anti-inflammatory properties,” the company explains in a press release. “It is produced in the body as a biological response and as a repair mechanism for inflammation. Levagen utilizes the endocannabinoid system for supporting joint function, reducing joint stiffness, and providing joint comfort.”
At SupplySide West, Gencor will also introduce a cold-water-dispersible version of Levagen, called Levagen+, that enhances bioavailability in aqueous environments, including the stomach, thanks to the use of LipiSperse dispersibility technology from an Australian company called Pharmako Biotechnologies, which is a partner of Gencor. The company claims Levagen+ supplies the largest amount of PEA, at over 90% loading, in a water-dispersible formulation.
Gencor says Levagen is supported by research and self-affirmed GRAS status. “PEA is the first of the next-generation anti-inflammatory analgesics,” said Chase Shryoc, vice president of business development, Gencor, in a press release.
Visit Gencor at SupplySide West Booth #4773